drugset / Trial / NCT04366063
Mesenchymal Stem Cell Therapy for SARS-CoV-2-related Acute Respiratory Distress Syndrome
Phase 2/3
Unknown
60 enrolled
Royan Institute
Shahid Beheshti University of Medical Sciences · collabTehran University of Medical Sciences · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
Acute Respiratory Distress Syndrome (ARDS) is the major cause of death in the COVID-19 pandemic. In this trial, the safety and efficacy of Mesenchymal Stem Cells (MSC) for the treatment of ARDS in COVID-19 patients will be assessed.
Timeline
- Start
- 2020-04-05
- Primary completion
- 2020-06-06
- Completion
- 2020-12-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cell therapy protocol 1 | Cell therapy | 1e+08 cells | Intravenous |
| Subject | extracellular vesicles | Other / unclassified | — | Intravenous |